The Effect of Microscopic Margin Status on Survival in Adult Retroperitoneal Soft Tissue Sarcomas
Overview
Oncology
Authors
Affiliations
Introduction: Resection is the primary treatment for retroperitoneal (RP) soft tissue sarcomas (STS). Whether obtaining microscopically negative margins (R0) improves overall survival (OS) over microscopically positive margins (R1) remains unclear.
Methods: Using the National Cancer Data Base, we identified adult patients diagnosed with RP STS after R0 or R1 resection from 1998 to 2011. We used a multivariable logistic regression model to identify clinicopathologic factors associated with margin status, including radiotherapy receipt. To assess differences in OS, the log-rank test, Cox proportional hazards regression, and propensity score matching were used.
Results: We identified 4015 patients; 2593 (64.6%) underwent R0 resection and 1422 (35.4%) underwent R1 resection. The most common histology was liposarcoma (2,371, 59.1%), median age was 60 years, and median follow up was 67 months. Median OS for R0 vs. R1 patients was 92 and 70 months, respectively (log-rank p < .001). Pre-operative RT was associated with increased probability of R0 resection (68.0% vs. 57.2%, p = .012). Multivariable regression showed R0 vs. R1 resection (HR 0.70, 95% CI 0.60-0.81, p < .001) was associated with improved survival, a finding confirmed on propensity score matching. Other significant predictors of OS included low tumor grade, younger age, smaller tumor size, liposarcoma histology, and receipt of RT (HR 0.81, 95% CI 0.70-0.93, p = .016).
Conclusions: Patients who undergo R0 resection for RP STS appear to experience superior OS compared with patients who had R1 resections.
Histology-Tailored Approach to Soft Tissue Sarcoma.
Gervais M, Basile G, Dulude J, Mottard S, Gronchi A Ann Surg Oncol. 2024; 31(12):7915-7929.
PMID: 39174839 DOI: 10.1245/s10434-024-15981-8.
Radiation therapy for retroperitoneal sarcoma: practice patterns in North America.
Ruff S, Heh V, Konieczkowski D, Onuma A, Dunlop H, Kim A Radiat Oncol. 2024; 19(1):38.
PMID: 38491404 PMC: 10943830. DOI: 10.1186/s13014-024-02407-8.
Surgical Management of Retroperitoneal Sarcoma.
Dominguez D, Sampath S, Agulnik M, Liang Y, Nguyen B, Trisal V Curr Oncol. 2023; 30(5):4618-4631.
PMID: 37232807 PMC: 10217420. DOI: 10.3390/curroncol30050349.
Liu W, Zou B, Tang M, Li X, Huang M, Chen W Ann Transl Med. 2022; 10(18):986.
PMID: 36267785 PMC: 9577802. DOI: 10.21037/atm-22-4222.
Retroperitoneal Sarcomas: a Current Review on Management.
Patkar S, Kattepur A, Khanna N, Bajpai J Indian J Surg Oncol. 2022; 13(3):542-558.
PMID: 36187536 PMC: 9515254. DOI: 10.1007/s13193-022-01520-y.